200815-49-2

• 常用中文名：酒石酸福莫特罗
• 常用英文名：Arformoterol tartrate
• CAS号：200815-49-2
• 分子式：C₂₃H₃₀N₂O₁₀
• 分子量：494.492
• 发布时间：2018-05-10 08:00:00
• 更新时间：2024-01-04 13:08:53
• Arformoterol tartrate is a long acting beta-adrenoceptor agonist drug indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization. It is the active (R,R)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.

名称

• 中文名: 酒石酸福莫特罗
• 英文名: (2R,3R)-2,3-dihydroxybutanedioic acid,N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide
• 中文别名: N-[2-羟基-5-[(1R)-1-羟基-2-[(1R)-2-(4-甲氧基苯基)-1-甲基乙基]氨基]乙基]苯基]甲酰胺-L-(+)-酒石酸盐; 酒石酸阿福特罗; 酒石酸阿福莫特罗
• 英文别名: UNII-5P8VJ2I235; (2R,3R)-2,3-Dihydroxybutandisäure--N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino}ethyl]phenyl}formamid(1:1); (2R,3R)-2,3-Dihydroxysuccinic acid - N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)-2-propanyl]amino}ethyl]phenyl}formamide (1:1); Butanedioic acid, 2,3-dihydroxy-, (2R,3R)-, compd. with formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]- (1:1); Brovana (TN); Brovana; (R,R)-Arformoterol tartrate; acide (2R,3R)-2,3-dihydroxybutanedioïque - N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(1R)-2-(4-méthoxyphényl)-1-méthyléthyl]amino}éthyl]phényl}formamide (1:1); UNII:5P8VJ2I235; (R,R)-Formoterol tartrate; N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino}ethyl]phenyl}formamide 2,3-dihydroxybutanedioate (salt); Arformoterol tartrate (USAN); Brovana Inhalation Solution; Arformoterol tartrate

物化性质

• 沸点: 603.2ºC at 760mmHg
• 分子式: C₂₃H₃₀N₂O₁₀
• 分子量: 494.492
• 精确质量: 494.190033
• PSA: 205.88000
• LogP: 1.20050
• 蒸汽压: 2.12E-15mmHg at 25°C
• 储存条件: 2~8℃

安全

• 危害码 (欧洲): Xi